Engene holdings inc. warrantsENGNW.US Overview
US StockHealthcare
(No presentation for ENGNW)
ENGNW Overall Performance
ENGNW AI Analysis & Strategy
ENGNW Recent Performance
-
Engene holdings inc. warrants
1.30%
Avg of Sector
0.61%
S&P500
ENGNW PowerScanner
ENGNW Key Information
ENGNW Valuation Metrics
ENGNW Earnings Table
ENGNW Profile
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.